Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Immunotherapy in non-small cell lung cancer patients: back to the future.].
Roberto M, Botticelli A, Cecere F, Cognetti F, Giusti R, Gelibter A, Lugini A, Nelli F, Nuti M, Santini D, Marchetti P. Roberto M, et al. Among authors: nuti m. Recenti Prog Med. 2019 Dec;110(12):587-593. doi: 10.1701/3278.32517. Recenti Prog Med. 2019. PMID: 31909761 Review. Italian.
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P. Botticelli A, et al. Among authors: nuti m. Oncotarget. 2017 Nov 1;8(59):99336-99346. doi: 10.18632/oncotarget.22242. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245905 Free PMC article.
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.
Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. Zizzari IG, et al. Among authors: nuti m. Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26. Cancer Immunol Res. 2018. PMID: 29700053
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Botticelli A, et al. Among authors: nuti m. J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3. J Transl Med. 2018. PMID: 30081936 Free PMC article.
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F, Giusti R, Tomassini A, Giampaoli O, Miccheli A, Zizzari IG, Nuti M, Putignani L, Marchetti P. Botticelli A, et al. Among authors: nuti m. J Transl Med. 2020 Feb 3;18(1):49. doi: 10.1186/s12967-020-02231-0. J Transl Med. 2020. PMID: 32014010 Free PMC article.
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
Botticelli A, Mezi S, Pomati G, Sciattella P, Cerbelli B, Roberto M, Mammone G, Cirillo A, Cassano A, Di Dio C, Cortellini A, Pizzuti L, Ronzino G, Salati M, Vici P, Polimeni A, Merlano MC, Nuti M, Marchetti P. Botticelli A, et al. Among authors: nuti m. Vaccines (Basel). 2020 Apr 20;8(2):191. doi: 10.3390/vaccines8020191. Vaccines (Basel). 2020. PMID: 32326034 Free PMC article.
275 results